B
Biomm
BIOM3
Last Price
52 Week Range
R$5.75 - R$10.66
Next Earnings Date
-
Next Earnings Date
-
Last Price
Biomm Investor Relations
Biomm Earnings Call Summary
Biomm Earnings
Estimates
Actual
Y-on-Y Change
Revenue
EPS
Transcripts
Events
About Biomm S.A.
B
Biomm S.A.
BIOM3
Biomm S.A. operates as a biotechnology company in Brazil. The company offers insulin products for the treatment of diabetes, including AFREZZA, a Human insulin powder for inhalation; GLARGILIN, a glargine insulin; WOSULIN N and WOSULIN R; and Lifepen G, a reusable insulin injection pen. It also provides Bevyx for the treatment of metastatic colorectal cancer; HERZUMA for the treatment of early-stage and metastatic breast cancer and metastatic gastric cancer with HER2-positive tumors; GHEMAXAN, an anticoagulant for the prophylaxis and treatment of deep vein thrombosis and pulmonary embolism, unstable angina, and in cases of acute myocardial infarction; and RANIVISIO for the treatment of vision problems related to abnormal blood vessel growth or fluid buildup in the retina. Biomm S.A. was incorporated in 2001 and is headquartered in Nova Lima, Brazil.
Biomm S.A. operates as a biotechnology company in Brazil. The company offers insulin products for the treatment of diabetes, including AFREZZA, a Human insulin powder for inhalation; GLARGILIN, a glargine insulin; WOSULIN N and WOSULIN R; and Lifepen G, a reusable ins...
Biomm S.A. operates as a biotechnology company in Brazil. The company offers insulin products for the treatment of diabetes, including AFREZZA, a Human insulin powder for inhalation; GLARGILIN, a glargine insulin; WOSULIN N and WOSULIN R; and Lifepen G, a reusable insulin injection pen. It also provides Bevyx for the treatment of metastatic colorectal cancer; HERZUMA for the treatment of early-stage and metastatic breast cancer and metastatic gastric cancer with HER2-positive tumors; GHEMAXAN, an anticoagulant for the prophylaxis and treatment of deep vein thrombosis and pulmonary embolism, unstable angina, and in cases of acute myocardial infarction; and RANIVISIO for the treatment of vision problems related to abnormal blood vessel growth or fluid buildup in the retina. Biomm S.A. was incorporated in 2001 and is headquartered in Nova Lima, Brazil.
Sector
Healthcare
Industry
Biotechnology
CEO
Marchezini, Heraldo
Employees
130
Website
www.biomm.comIPO Date
2000-01-11
Headquarters
705 – Lagoa dos Ingleses, Avenida Regent, Alphaville, Nova Lima, Minas Gerais, 34018-000, Brazil
Gainify
Features
Platform
Resources
Learn
Socials
NEWSLETTER
Market data is sourced from S&P Global Market Intelligence. All insights and analysis are developed by Gainify. Copyright © 2026, S&P Global Market Intelligence. All rights reserved.
View Data ProvidersNEWSLETTER
Market data is sourced from S&P Global Market Intelligence. All insights and analysis are developed by Gainify. Copyright © 2026, S&P Global Market Intelligence. All rights reserved.
View Data ProvidersGainify provides tools and content designed to help users explore and understand the world of investing. All information available through our platform is for educational and informational use only. It is not intended as financial, investment or legal advice, and should not be treated as a recommendation or endorsement of any investment approach.
Our content is general in nature and does not account for your personal financial circumstances. Any investment decisions you make are your responsibility. We strongly recommend speaking with a licensed financial advisor or professional before acting on any information found on Gainify. Before using Gainify, please review our Terms of Service.
Our content is general in nature and does not account for your personal financial circumstances. Any investment decisions you make are your responsibility. We strongly recommend speaking with a licensed financial advisor or professional before acting on any information found on Gainify. Before using Gainify, please review our Terms of Service.
© 2026 Gainify. All rights reserved.